# Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

> **NCT06413121** · PHASE3 · RECRUITING · sponsor: **Serum Institute of India Pvt. Ltd.** · enrollment: 1557 (estimated)

## Conditions studied

- Diptheria Immunization
- Tetanus Immunization
- Pertussis Immunization
- Hepatitis B Immunization
- Haemophilus Influenzae Type B Immunization
- Polio Immunization

## Interventions

- **BIOLOGICAL:** Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
- **BIOLOGICAL:** Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV

## Key facts

- **NCT ID:** NCT06413121
- **Lead sponsor:** Serum Institute of India Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2025-08-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 1557 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413121, "Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06413121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*